SacramentoKings Posted - 04/30/24

$EXAI maybe we need some more class action lawsuits. Seems to be helping our shareprice?

NoTworrieD_ Posted - 04/30/24

$EXAI got in at 3.98

11thestate Posted - 04/30/24

$EXAI is currently facing an investigation over allegations that the company failed to disclose the improper conduct of the CEO. Join submission info and details:https://11thestate.com/cases/exscientia-investor-suit

sweeptofill Posted - 04/29/24

$EXAI https://www.bernlieb.com/cases/exscientiaplc-exai-shareholder-lawsuit-class-action-fraud-stock-735/

SacramentoKings Posted - 04/29/24

$EXAI no news? What in the inside trading is happening here?

NOFAPGOD Posted - 04/25/24

$QSI hi guys, I did my DD, QSI is literally the best biotech company in the world. Ignore the $EXAI $RXRX the folks as $NVDA should take NGS and make AI software for that... not the old dna way that takes decades even with AI to get one tiny sub-illness pipeline.

SacramentoKings Posted - 04/23/24

$EXAI wow this board is dead..

SacramentoKings Posted - 04/16/24

@Didgeman I’ll stay on the sidelines for now. Have you looked into Shrodinger $SDGR or Exscientia $EXAI ?? Both look promising platforms.

SacramentoKings Posted - 04/16/24

$RXRX which is a better buy between RXRX and $EXAI ? RXRX investment by NVDA & Cathy woods, questionable pipeline (not much information), pending big partners EXAI big partnerships with Sanofi and Merck for potentially billions, CEO fired for sexual affairs with employees. Both seem to be top 5 AI platforms for drug discovery. I have a little more faith in Chris Gibson and his relationship with Jenson, but if Exscentia can hire a top CEO in the AI space, they could have a very bright future.

TheMarketsTheTarget Posted - 04/15/24

$EXAI Not. Good.

camraptor Posted - 04/04/24

$EXAI where is the bottom? I'm not back in yet.

DailyStocksPicks Posted - 03/27/24

My Oversold pick #2 for today is $CABA This company is working on developing targeted cell therapies for autoimmune diseases. With FDA designations advancing its clinical trials and a solid financial strategy aimed at supporting its pipeline, analysts also see significant growth potential despite its current financial losses​​​​. $EXAI, $ALLO, $TRML, $HLVX https://youtu.be/7pOcCYEQIxM

TICKERTUTOR Posted - 03/27/24

$IBIO So just for context, this is how much other AI drug discovery platform cos are being valued here… $SDGR 1.85B, $RXRX 2.4B, $EXAI 725M $ABSI 600M. No suggestion here… just context.

Stocksrunner Posted - 03/21/24

📉 Today's Top Losers in the News 📉 $SPIR seeks to raise $30M in a direct offering, shares dip. $FIVE Investors puzzled as Five Below's shares drop despite strong Q4 results. $IFRX reports Q4 loss missing revenue estimates. $EXAI plc shares slide, check out their Q4 earnings call transcript. $CHWY disappointing outlook prompts sell-offs, shares down 25% in 2024. ℹ️ Stay informed and adapt your trading strategy accordingly.

shoagh12 Posted - 03/21/24

$EXAI

_www_larval_com_ Posted - 03/21/24

$EXAI -9%[-15%] $CZOO 8%[23%] $AMTX -8%[16%] $XTLB 7%[8%] $NNOX 7%[11%] most notable movement within the first minutes of trading.

DonCorleone77 Posted - 03/21/24

$EXAI Exscientia files $300M mixed securities shelf

shoagh12 Posted - 03/21/24

$EXAI starting Green today

epsguid Posted - 03/21/24

$EXAI reported a loss of $0.42, consensus was ($0.44) via @eWhispers #epsbeat http://eps.sh/d/exai

Meltingflame Posted - 03/21/24

$EXAI I'm not entirely sure how to read (interpret) this result. Truly! And, that's after several efforts. Longterm bullish certainly.

DonCorleone77 Posted - 03/21/24

$EXAI Exscientia reports Q4 EPS (42c), consensus (35c) Reports Q4 revenue $3.1M, consensus $17.05M. "In 2023, we significantly expanded our technological capabilities with the opening of our automation facility, concentrated our internal research on high value oncology targets and steadily progressed multiple new and existing programmes with our large pharma partners," said David Hallett, interim CEO and chief scientific officer of Exscientia. "In 2024 we will continue to advance our pipeline programmes through clinical development. This includes GTAEXS617 ('617), our CDK7 inhibitor currently in a Phase 1/2 clinical trial; LSD1, for which we anticipate initiating a Phase 1 patient study this year; and MALT1, which continues to progress through IND-enabling studies. In addition, we look forward to advancing our partnered programmes through potential milestones, while simultaneously inking new partnerships and expanding our technological capabilities to further cement our leadership..

Stock_Titan Posted - 03/21/24

$EXAI Exscientia Business and Financial Update for the Full Year 2023 https://www.stocktitan.net/news/EXAI/exscientia-business-and-financial-update-for-the-full-year-7m3uuiikd6gf.html

shoagh12 Posted - 03/21/24

$EXAI 10$ soon

Wigglyick Posted - 03/20/24

$EXAI

Wigglyick Posted - 03/20/24

$EXAI I always get excited when time, space & price all converge at a certain point. It’s like looking at a snowflake. Good luck

Shantanu2011 Posted - 03/20/24

$EXAI it should be a good morning tomorrow

Meltingflame Posted - 03/20/24

$EXAI Earnings preview. Earnings to be released before open tomorrow.

shoagh12 Posted - 03/18/24

$EXAI 10$ soon

Stock_Titan Posted - 03/14/24

$EXAI Exscientia to Report Full Year 2023 Financial Results on March 21, 2024 https://www.stocktitan.net/news/EXAI/exscientia-to-report-full-year-2023-financial-results-on-march-21-w6cez65o0khm.html

shoagh12 Posted - 03/14/24

$EXAI 10$ soon